Pharmacokinetics of pure silybin diastereoisomers and identification of their metabolites in rat plasma

Journal of Functional Foods

Volumn 14, Issue , 2015, Pages 570-580

  Marhol, Petr ^a   Bednář, Petr ^b   Kolářová, Petra ^a,c   Večeřa, Rostislav ^b   Ulrichová, Jitka ^b   Tesařová, Eva ^c   Vavříková, Eva ^a   Kuzma, Marek ^a   Křen, Vladimír ^a  

^a INSTITUTE OF MICROBIOLOGY   (Czech Republic)

^b PALACKÝ UNIVERSITY   (Czech Republic)

^c CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Benzofuranone; Silibinin; Silybin; Silybin glucuronide; Silybin sulfate; Silymarin

Indexed keywords

RATTUS; SILYBUM MARIANUM;

EID: 84926355452     PISSN: 17564646     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jff.2015.02.031     Document Type: Article

References (40)

1. Biedermann D., Vavříková E., Cvak L., Křen V. Chemistry of silybin. Natural Product Reports 2014, 31:1138-1157.
2. Brinda B.J., Zhu H.J., Markowitz J.S. A sensitive LC-MS/MS assay for the simultaneous analysis of the major active components of silymarin in human plasma. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences 2012, 902:1-9.
3. Charrier C., Azerad R., Marhol P., Purchartová K., Kuzma M., Křen V. Preparation of silybin phase II metabolites: Streptomyces catalyzed glucuronidation. Journal of Molecular Catalysis B: Enzymatic 2014, 102:167-173.
4. Choppin J., Desplaces A. Effects of silybin on experimental phalloidine poisoning. Arzneimittel-Forschung/Drug Research 1978, 28-1:636-641.
5. Deep G., Oberlies N.H., Kroll D.J., Agarwal R. Identifying the differential effects of silymarin constituents on cell growth and cell cycle regulatory molecules in human prostate cancer cells. International Journal of Cancer 2008, 123:41-50.
6. Fraschini F., Demartini G., Esposti D. Pharmacology of silymarin. Clinical Drug Investigation 2002, 22:51-65.
7. Gažák R., Marhol P., Purchartová K., Monti D., Biedermann D., Riva S., Cvak L., Křen V. Large-scale separation of silybin diastereoisomers using lipases. Process Biochemistry 2010, 45:1657-1663.
8. Gažák R., Sedmera P., Vrbacký M., Vostálová J., Drahota Z., Marhol P., Walterová D., Křen V. Molecular mechanisms of silybin and 2,3-dehydrosilybin antiradical activity-role of individual hydroxyl groups. Free Radical Biology and Medicine 2009, 46:745-758.
9. Gažák R., Trouillas P., Biedermann D., Fuksová K., Marhol P., Kuzma M., Křen V. Base-catalyzed oxidation of silybin and isosilybin into 2,3-dehydro derivatives. Tetrahedron Letters 2013, 54:315-317.
10. Gažák R., Walterová D., Křen V. Silybin and silymarin - New and emerging applications in medicine. Current Medicinal Chemistry 2007, 14:315-338.
11. Gunaratna C., Zhang T. Application of liquid chromatography-electrospray ionization-ion trap mass spectrometry to investigate the metabolism of silibinin in human liver microsomes. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences 2003, 794:303-310.
12. Hackett E.S., Mama K.R., Twedt D.C., Gustafson D.L. Pharmacokinetics and safety of silibinin in horses. American Journal of Veterinary Research 2013, 74:1327-1332.
13. Han Y.H., Lou H.X., Ren D.M., Sun L.R., Ma B., Ji M. Stereoselective metabolism of silybin diastereoisomers in the glucuronidation process. Journal of Pharmaceutical and Biomedical Analysis 2004, 34:1071-1078.
14. Hoh C.S.L., Boocock D.J., Marczylo T.H., Brown V.A., Cai H., Steward W.P., Berry D.P., Gescher A.J. Quantitation of silibinin, a putative cancer chemopreventive agent derived from milk thistle (Silybum marianum), in human plasma by high-performance liquid chromatography and identification of possible metabolites. Journal of Agricultural and Food Chemistry 2007, 55:2532-2535.
15. Jančová P., Anzenbacherová E., Papoušková B., Lemr K., Lužná P., Veinlichová A., Anzenbacher P., Šimánek V. Silybin is metabolized by cytochrome P4502C8 in vitro. Drug Metabolism and Disposition 2007, 35:2035-2039.
16. Jančová P., Anzenbacherová E., Šiller M., Křen V., Anzenbacher P., Šimánek V. Stereoselective metabolism of silybin by UDP glucuronosyltransferases in vitro. Xenobiotica 2011, 41:743-751.
17. Javed S., Kohli K., Ali M. Reassessing bioavailability of silymarin. Alternative Medicine Review 2011, 16:239-249.
18. Kosina P., Bartek J. Determination of silybin in blood plasma using high performance liquid chromatography with solid phase extraction. Chemické Listy 2000, 94:1115-1117.
19. Křen V., Gažák R., Purchartová K., Marhol P., Biedermann D., Sedmera P. Chemoenzymatic preparative separation of silybins A and B. Journal of Molecular Catalysis B: Enzymatic 2009, 61:247-251.
20. Křen V., Marhol P., Purchartová K., Gabrielová E., Modrianský M. Biotransformation of silybin and its congeners. Current Drug Metabolism 2013, 14:1009-1021.
21. Křen V., Ulrichová J., Kosina P., Stevenson D., Sedmera P., Přikrylová V., Halada P., Šimánek V. Chemoenzymatic preparation of silybin β-glucuronides and their biological evaluation. Drug Metabolism and Disposition 2000, 28:1513-1517.
22. Kubo I., Nihei K., Shimizu K. Oxidation products of quercetin catalyzed by mushroom tyrosinase. Bioorganic & Medicinal Chemistry 2004, 12:5343-5347.
23. Lee D.Y.W., Liu Y.Z. Molecular structure and stereochemistry of silybin A, silybin B, isosilybin A, and isosilybin B, isolated from Silybum marianum (Milk thistle). Journal of Natural Products 2003, 66:1171-11174.
24. Lee H.B., Blaufox M.D. Blood-volume in the rat. Journal of Nuclear Medicine 1985, 26:72-76.
25. Li W., Han J.P., Li Z.W., Li X.X., Hou S.P., Liu C.X. Preparative chromatographic purification of diastereomers of silybin and their quantification in human plasma by liquid chromatography-tandem mass spectrometry. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences 2008, 862:51-57.
26. Marhol P., Hartog A.F., Van Der Horst M.A., Wever R., Purchartová K., Fuksová K., Kuzma M., Cvačka J., Křen V. Preparation of silybin and isosilybin sulfates by sulfotransferase from Desulfitobacterium hafniense. Journal of Molecular Catalysis B: Enzymatic 2013, 89:24-27.
27. Nagarajan S., Namasivayam N. Silibinin alleviates hyperlipidaemia, restores mucin content, modulates TGF-β and fosters apoptosis in experimental rat colon carcinogenesis. Journal of Functional Foods 2014, 11:472-481.
28. Pietrangelo A., Borella F., Casalgrandi G., Montosi G., Ceccarelli D., Gallesi D., Giovannini F., Gasparetto A., Masini A. Antioxidant activity of silybin in vivo during long-term iron overload in rats. Gastroenterology 1995, 109:1941-1949.
29. Purchartová K., Engels L., Marhol P., Šulc M., Kuzma M., Slámová K., Elling L., Křen V. Enzymatic preparation of silybin phase II metabolites: Sulfation using aryl sulfotransferase from rat liver. Applied Microbiology and Biotechnology 2013, 97:10391-10398.
30. Rickling B., Hans B., Kramarczyk R., Krumbiegel G., Weyhenmeyer R. Two high-performance liquid-chromatographic assays for the determination of free and total silibinin diastereomers in plasma using column-switching with electrochemical detection and reversed-phase chromatography with ultraviolet detection. Journal of Chromatography. B, Biomedical Applications 1995, 670:267-277.
31. Tharp R. Half-life calculator© for Windows™ Accessed 12.03.14. http://www.rxkinetics.com/half_life.html.
32. Theodosiou E., Purchartová K., Stamatis H., Kolisis F., Křen V. Bioavailability of silymarin flavonolignans: Drug formulations and biotransformation. Phytochemistry Reviews 2014, 13:1-18.
33. Vacek J., Papoušková B., Vrba J., Zatloukalová M., Křen V., Ulrichová J. LC-MS metabolic study on quercetin and taxifolin galloyl esters using human hepatocytes as toxicity and biotransformation in vitro cell model. Journal of Pharmaceutical and Biomedical Analysis 2013, 86:135-142.
34. Valenzuela A., Guerra R., Videla L.A. Antioxidant properties of the flavonoids silybin and (+)-cyanidanol-3 - Comparison with butylated hydroxyanisole and butylated hydroxytoluene. Planta Medica 1986, 438-440.
35. Wellington K., Jarvis B. Silymarin: A review of its clinical properties in the management of hepatic disorders. Biodrugs: Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy 2001, 15:465-489.
36. Wen Z., Dumas T.E., Schrieber S.J., Hawke R.L., Fried M.W., Smith P.C. Pharmacokinetics and metabolic profile of free, conjugated, and total silymarin flavonolignans in human plasma after oral administration of milk thistle extract. Drug Metabolism and Disposition 2008, 36:65-72.
37. Weyhenmeyer R., Mascher H., Birkmayer J. Study on dose-linearity of the pharmacokinetics of silibinin diastereomers using a new stereospecific assay. International Journal of Clinical Pharmacology and Therapeutics 1992, 30:134-138.
38. Wu J.W., Lin L.C., Hung S.C., Chi C.W., Tsai T.H. Analysis of silibinin in rat plasma and bile for hepatobiliary excretion and oral bioavailability application. Journal of Pharmaceutical and Biomedical Analysis 2007, 45:635-641.
39. Zhao J.F., Agarwal R. Tissue distribution of silibinin, the major active constituent of silymarin, in mice and its association with enhancement of phase II enzymes: Implications in cancer chemoprevention. Carcinogenesis 1999, 20:2101-2108.
40. Zhu H.J., Brinda B.J., Chavin K.D., Bernstein H.J., Patrick K.S., Markowitz J.S. An assessment of pharmacokinetics and antioxidant activity of free silymarin flavonolignans in healthy volunteers: A dose escalation study. Drug Metabolism and Disposition 2013, 41:1679-1685.